Show simple item record

dc.contributor.authorAarntzen, EHJG
dc.contributor.authorHeijmen, L
dc.contributor.authorOyen, WJG
dc.date.accessioned2018-01-30T11:44:30Z
dc.date.issued2018-04
dc.identifier.citationJournal of nuclear medicine : official publication, Society of Nuclear Medicine, 2018, 59 (4), pp. 551 - 556
dc.identifier.issn0161-5505
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1036
dc.identifier.eissn1535-5667
dc.identifier.doi10.2967/jnumed.117.198184
dc.description.abstractDriven by the continuous improvement in the accuracy of cross-sectional imaging, image-guided minimally invasive local ablative therapies have received incremental interest over the past few years. In this article, we systematically review the currently available literature on 18F-FDG PET/CT to monitor the efficacy of these local ablative therapies. By including all local ablative treatment modalities, tumor types, and organ sites, we provide a comprehensive overview of the current status, identify general patterns across studies, and provide recommendations for future studies and clinical practice. The Quality Assessment of Diagnostic Accuracy Studies (QUADAS) criteria were used to assess the quality of the reported diagnostic accuracy of the retrieved studies. Data in the literature suggest that 18F-FDG PET/CT is a highly accurate tool to assess the technical success of local treatment, to identify residual or recurrent tumor early after intervention, and to provide prognostic and predictive information. However, prospective interventional studies based on 18F-FDG PET/CT findings of disease activity are mandatory to develop uniform and quantitative criteria for PET evaluation. Moreover, the optimal timing of 18F-FDG PET/CT after treatment may vary according to the location of the disease, with very early imaging being possible in solid organs such as the liver but posttreatment imaging being challenging for 3 mo in a location such as the lung parenchyma.
dc.formatPrint-Electronic
dc.format.extent551 - 556
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://www.rioxx.net/licenses/all-rights-reserved
dc.subjectHumans
dc.subjectNeoplasms
dc.subjectFluorodeoxyglucose F18
dc.subjectTreatment Outcome
dc.subjectAblation Techniques
dc.subjectPositron Emission Tomography Computed Tomography
dc.title18F-FDG PET/CT in Local Ablative Therapies: A Systematic Review.
dc.typeJournal Article
dcterms.dateAccepted2017-12-13
rioxxterms.versionofrecord10.2967/jnumed.117.198184
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2018-04
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfJournal of nuclear medicine : official publication, Society of Nuclear Medicine
pubs.issue4
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Molecular Imaging
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Molecular Imaging
pubs.publication-statusPublished
pubs.volume59
pubs.embargo.termsNo embargo
icr.researchteamTranslational Molecular Imagingen_US
dc.contributor.icrauthorOyen, Willem


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record